Clinical Data ASCO26: AZ triplet makes waves in frontline liver cancer PharmaphorumEMERALD-3 suggests a triplet regimen based on AstraZeneca's Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma.OncologyRead full story pharminent June 2, 2026 (Last updated: June 4, 2026) Pharmaphorum EMERALD-3 suggests a triplet regimen based on AstraZeneca’s Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma. Oncology Read full story Post navigation Previous: CordenPharma inks AmbioPharm buyout to continue peptide production expansionNext: Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026